Amgen’s PCSK9 Mixed Bag, Regeneron & GSK’s Genomics Bet, and Healthcare Vote Stalls

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.